journal
MENU ▼
Read by QxMD icon Read
search

Lancet Infectious Diseases

journal
https://www.readbyqxmd.com/read/28522338/year-round-influenza-immunisation-during-pregnancy-in-nepal-a-phase-4-randomised-placebo-controlled-trial
#1
Mark C Steinhoff, Joanne Katz, Janet A Englund, Subarna K Khatry, Laxman Shrestha, Jane Kuypers, Laveta Stewart, Luke C Mullany, Helen Y Chu, Steven C LeClerq, Naoko Kozuki, Monica McNeal, Adriana M Reedy, James M Tielsch
BACKGROUND: Influenza immunisation during pregnancy is recommended but not widely implemented in some low-income regions. We assessed the safety and efficacy in mothers and infants of year-round maternal influenza immunisation in Nepal, where influenza viruses circulate throughout the year. METHODS: In this phase 4, randomised, placebo-controlled trial, we enrolled two consecutive sequential annual cohorts of pregnant women from the Sarlahi district in southern Nepal...
May 15, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28522337/maternal-influenza-immunisation-to-reduce-influenza-infections-and-low-birthweight-in-infants-in-resource-limited-countries
#2
Paul Loubet, Odile Launay
No abstract text is available yet for this article.
May 15, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28499828/estimating-the-future-burden-of-multidrug-resistant-and-extensively-drug-resistant-tuberculosis-in-india-the-philippines-russia-and-south-africa-a-mathematical-modelling-study
#3
Aditya Sharma, Andrew Hill, Ekaterina Kurbatova, Martie van der Walt, Charlotte Kvasnovsky, Thelma E Tupasi, Janice C Caoili, Maria Tarcela Gler, Grigory V Volchenkov, Boris Y Kazennyy, Olga V Demikhova, Jaime Bayona, Carmen Contreras, Martin Yagui, Vaira Leimane, Sang Nae Cho, Hee Jin Kim, Kai Kliiman, Somsak Akksilp, Ruwen Jou, Julia Ershova, Tracy Dalton, Peter Cegielski
BACKGROUND: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are emerging worldwide. The Green Light Committee initiative supported programmatic management of drug-resistant tuberculosis in 90 countries. We used estimates from the Preserving Effective TB Treatment Study to predict MDR and XDR tuberculosis trends in four countries with a high burden of MDR tuberculosis: India, the Philippines, Russia, and South Africa. METHODS: We calibrated a compartmental model to data from drug resistance surveys and WHO tuberculosis reports to forecast estimates of incident MDR and XDR tuberculosis and the percentage of incident MDR and XDR tuberculosis caused by acquired drug resistance, assuming no fitness cost of resistance from 2000 to 2040 in India, the Philippines, Russia, and South Africa...
May 9, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28499827/drug-resistant-tuberculosis-threatens-who-s-end-tb-strategy
#4
Mariandyshev Andrei, Eliseev Platon
No abstract text is available yet for this article.
May 9, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28495525/latent-tuberculosis-infection-the-final-frontier-of-tuberculosis-elimination-in-the-usa
#5
REVIEW
Philip A LoBue, Jonathan H Mermin
Since 1989, the USA has been pursuing the goal of tuberculosis elimination. After substantial progress during the past two decades, the rate of tuberculosis cases in the USA each year has now levelled off and remains well above the elimination threshold. Both epidemiological data and modelling underline the necessity of addressing latent tuberculosis infection if further progress is to be made in eliminating the disease. In this Personal View we explore next steps towards elimination. Given the estimated prevalence of latent tuberculosis infection, compared with the limited testing and treatment that currently occur, a major new effort is required...
May 8, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28483417/parenteral-protein-based-rotavirus-vaccine
#6
Miguel O'Ryan, Benjamin A Lopman
No abstract text is available yet for this article.
May 5, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28483416/the-relentless-march-of-cryptococcal-meningitis
#7
Peter R Williamson
No abstract text is available yet for this article.
May 5, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28483415/global-burden-of-disease-of-hiv-associated-cryptococcal-meningitis-an-updated-analysis
#8
Radha Rajasingham, Rachel M Smith, Benjamin J Park, Joseph N Jarvis, Nelesh P Govender, Tom M Chiller, David W Denning, Angela Loyse, David R Boulware
BACKGROUND: Cryptococcus is the most common cause of meningitis in adults living with HIV in sub-Saharan Africa. Global burden estimates are crucial to guide prevention strategies and to determine treatment needs, and we aimed to provide an updated estimate of global incidence of HIV-associated cryptococcal disease. METHODS: We used 2014 Joint UN Programme on HIV and AIDS estimates of adults (aged >15 years) with HIV and antiretroviral therapy (ART) coverage...
May 5, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28483414/safety-and-immunogenicity-of-a-parenteral-p2-vp8-p-8-subunit-rotavirus-vaccine-in-toddlers-and-infants-in-south-africa-a-randomised-double-blind-placebo-controlled-trial
#9
Michelle J Groome, Anthonet Koen, Alan Fix, Nicola Page, Lisa Jose, Shabir A Madhi, Monica McNeal, Len Dally, Iksung Cho, Maureen Power, Jorge Flores, Stanley Cryz
BACKGROUND: Efficacy of live oral rotavirus vaccines is reduced in low-income compared with high-income settings. Parenteral non-replicating rotavirus vaccines might offer benefits over oral vaccines. We assessed the safety and immunogenicity of the P2-VP8-P[8] subunit rotavirus vaccine at different doses in South African toddlers and infants. METHODS: This double-blind, randomised, placebo-controlled, dose-escalation trial was done at a single research unit based at a hospital in South Africa in healthy HIV-uninfected toddlers (aged 2 to <3 years) and term infants (aged 6 to <8 weeks, without previous rotavirus vaccination)...
May 5, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28478936/corrections
#10
(no author information available yet)
No abstract text is available yet for this article.
May 3, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28461209/insights-from-clinical-research-completed-during-the-west-africa-ebola-virus-disease-epidemic
#11
REVIEW
Amanda Rojek, Peter Horby, Jake Dunning
The west Africa Ebola virus disease (EVD) epidemic was extraordinary in scale. Now that the epidemic has ended, it is a relevant time to examine published studies with direct relevance to clinical care and, more broadly, to examine the implications of the clinical research response mounted. Clinically relevant research includes literature detailing risk factors for and clinical manifestations of EVD, laboratory and other investigation findings in patients, experimental vaccine and therapeutic clinical trials, and analyses of survivor syndrome...
April 28, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28461208/expanding-the-armamentarium-for-the-treatment-of-clostridium-difficile-infection
#12
Simon D Goldenberg
No abstract text is available yet for this article.
April 28, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28461207/efficacy-and-safety-of-ridinilazole-compared-with-vancomycin-for-the-treatment-of-clostridium-difficile-infection-a-phase-2-randomised-double-blind-active-controlled-non-inferiority-study
#13
Richard J Vickers, Glenn S Tillotson, Richard Nathan, Sabine Hazan, John Pullman, Christopher Lucasti, Kenneth Deck, Bruce Yacyshyn, Benedict Maliakkal, Yves Pesant, Bina Tejura, David Roblin, Dale N Gerding, Mark H Wilcox
BACKGROUND: Clostridium difficile infection is the most common health-care-associated infection in the USA. We assessed the safety and efficacy of ridinilazole versus vancomycin for treatment of C difficile infection. METHODS: We did a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Participants with signs and symptoms of C difficile infection and a positive diagnostic test result were recruited from 33 centres in the USA and Canada and randomly assigned (1:1) to receive oral ridinilazole (200 mg every 12 h) or oral vancomycin (125 mg every 6 h) for 10 days...
April 28, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28457597/global-epidemiology-of-non-influenza-rna-respiratory-viruses-data-gaps-and-a-growing-need-for-surveillance
#14
REVIEW
Julian W Tang, Tommy T Lam, Hassan Zaraket, W Ian Lipkin, Steven J Drews, Todd F Hatchette, Jean-Michel Heraud, Marion P Koopmans
Together with influenza, the non-influenza RNA respiratory viruses (NIRVs), which include respiratory syncytial virus, parainfluenza viruses, coronavirus, rhinovirus, and human metapneumovirus, represent a considerable global health burden, as recognised by WHO's Battle against Respiratory Viruses initiative. By contrast with influenza viruses, little is known about the contemporaneous global diversity of these viruses, and the relevance of such for development of pharmaceutical interventions. Although far less advanced than for influenza, antiviral drugs and vaccines are in different stages of development for several of these viruses, but no interventions have been licensed...
April 27, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28454675/maximising-the-impact-of-inactivated-polio-vaccines
#15
Elizabeth B Brickley, Peter F Wright
No abstract text is available yet for this article.
April 25, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28454674/immunogenicity-and-safety-of-three-aluminium-hydroxide-adjuvanted-vaccines-with-reduced-doses-of-inactivated-polio-vaccine-ipv-al-compared-with-standard-ipv-in-young-infants-in-the-dominican-republic-a-phase-2-non-inferiority-observer-blinded-randomised-and
#16
Luis Rivera, Rasmus S Pedersen, Lourdes Peña, Klaus J Olsen, Lars V Andreasen, Ingrid Kromann, Pernille I Nielsen, Charlotte Sørensen, Jes Dietrich, Ananda S Bandyopadhyay, Birgit Thierry-Carstensen
BACKGROUND: Cost and supply constraints are key challenges in the use of inactivated polio vaccine (IPV). Dose reduction through adsorption to aluminium hydroxide (Al) is a promising option, and establishing its effectiveness in the target population is a crucial milestone in developing IPV-Al. The aim of this clinical trial was to show the non-inferiority of three IPV-Al vaccines to standard IPV. METHODS: In this phase 2, non-inferiority, observer-blinded, randomised, controlled, single-centre trial in the Dominican Republic, healthy infants aged 6 weeks, not previously polio vaccinated, were allocated after computer-generated randomisation by block-size of four, to receive one of four IPV formulations (three-times reduced dose [1/3 IPV-Al], five-times reduced dose [1/5 IPV-Al], ten-times reduced dose [1/10 IPV-Al], or IPV) intramuscularly in the thigh at 6, 10, and 14 weeks of age...
April 25, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28462810/corrections
#17
(no author information available yet)
No abstract text is available yet for this article.
April 24, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28442294/who-benefits-from-antimicrobial-combination-therapy
#18
Mathias W Pletz, Stefan Hagel, Christina Forstner
No abstract text is available yet for this article.
April 21, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28442293/effect-of-appropriate-combination-therapy-on-mortality-of-patients-with-bloodstream-infections-due-to-carbapenemase-producing-enterobacteriaceae-increment-a-retrospective-cohort-study
#19
Belén Gutiérrez-Gutiérrez, Elena Salamanca, Marina de Cueto, Po-Ren Hsueh, Pierluigi Viale, José Ramón Paño-Pardo, Mario Venditti, Mario Tumbarello, George Daikos, Rafael Cantón, Yohei Doi, Felipe Francisco Tuon, Ilias Karaiskos, Elena Pérez-Nadales, Mitchell J Schwaber, Özlem Kurt Azap, Maria Souli, Emmanuel Roilides, Spyros Pournaras, Murat Akova, Federico Pérez, Joaquín Bermejo, Antonio Oliver, Manel Almela, Warren Lowman, Benito Almirante, Robert A Bonomo, Yehuda Carmeli, David L Paterson, Alvaro Pascual, Jesús Rodríguez-Baño
BACKGROUND: The best available treatment against carbapenemase-producing Enterobacteriaceae (CPE) is unknown. The objective of this study was to investigate the effect of appropriate therapy and of appropriate combination therapy on mortality of patients with bloodstream infections (BSIs) due to CPE. METHODS: In this retrospective cohort study, we included patients with clinically significant monomicrobial BSIs due to CPE from the INCREMENT cohort, recruited from 26 tertiary hospitals in ten countries...
April 21, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28433706/global-perspectives-on-maternal-immunisation
#20
Ajoke Sobanjo-Ter Meulen, Sharon Bergquist, Keith P Klugman
No abstract text is available yet for this article.
April 19, 2017: Lancet Infectious Diseases
journal
journal
20187
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"